免疫性血小板减少症的新型疗法
当前免疫性血小板减少症(ITP)的治疗可使超过三分之二的患者获得止血性血小板计数,但部分患者应答不足,仍需其他疗法。本文基于ITP现有病理生理机制,综述了靶向减少血小板破坏(如抗CD40、CD38、免疫蛋白酶体单抗、抑制新生儿Fc受体、FcγR功能抑制、补体C1s抑制剂、去唾液酸化抑制)及促进血小板生成(新型口服血小板生成素受体激动剂、低强度激光)的新疗法开发现状。
要点
- 现有ITP治疗可使超过三分之二患者获得止血性血小板计数,但部分患者应答不足。
- 新型疗法基于病理生理机制,靶向减少抗体产生、阻断Fc受体、抑制补体或促进血小板生成。
- 成功的新型ITP疗法可能为其他自身免疫性疾病提供治疗路径。
核心结论
- 多种基于ITP病理生理机制的新型疗法正在开发中,旨在为现有治疗应答不足的患者提供选择。
- 成功的新型ITP疗法可能为其他自身免疫性疾病提供治疗路径。
主要发现
- 当前ITP治疗可使超过三分之二的患者获得止血性血小板计数,但部分患者应答不足。
- 靶向减少血小板破坏的策略包括:抗CD40、CD38和免疫蛋白酶体单抗进行免疫抑制以减少抗血小板抗体产生;抑制新生儿Fc受体以物理降低抗血小板抗体浓度。
- 靶向吞噬系统的策略包括:葡萄球菌蛋白A、超唾液酸化IgG、聚合Fc片段或Bruton激酶抑制FcγR功能。
- 补体C1s抑制剂正在测试中,抑制血小板去唾液酸化也可能发挥作用。
- 促进血小板生成的策略包括新型口服血小板生成素受体激动剂或低强度激光改善线粒体活性并防止巨核细胞凋亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current therapies for immune thrombocytopenia (ITP) are successful in providing a haemostatic platelet count in over two-thirds of patients. Still, some patients have an inadequate response and there is a need for other therapies. A number of novel therapies for ITP are currently being developed based upon the current pathophysiology of ITP. Many therapies are targetted at reducing platelet destruction by decreasing anti-platelet antibody production by immunosuppression with monoclonal antibodies targetted against CD40, CD38 and the immunoproteasome or physically reducing the anti-platelet antibody concentration by inhibition of the neonatal Fc receptor. Others target the phagocytic system by inhibiting FcγR function with staphylococcal protein A, hypersialylated IgG, polymeric Fc fragments, or Bruton kinase. With a recognition that platelet destruction is also mediated by complement, inhibitors of C1s are also being tested. Inhibition of platelet desialylation may also play a role. Other novel therapies promote platelet production with new oral thrombopoietin receptor agonists or the use of low-level laser light to improve mitochondrial activity and prevent megakaryocyte apoptosis. This review will focus on these novel mechanisms for treating ITP and assess the status of treatments currently under development. Successful new treatments for ITP might also provide a pathway to treat other autoimmune disorders.
引用
- Kuter DJ. Novel therapies for immune thrombocytopenia. Br J Haematol. 2021. PMID: 34611885. doi:10.1111/bjh.17872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。